GLAXOSMITHKLINE PHARMACEUTICALS LTD. - Updates

With reference to the earlier letter dated February 12, 2015 regarding GSK and Novartis deal, GlaxoSmithKline Pharmaceuticals Ltd has now informed BSE that the Company has completed its transaction with Novartis Healthcare Pvt. Ltd. (Novartis India) on September 30, 2015 whereby the Company has acquired Novartis vaccines business and divested its marketed oncology portfolio to Novartis India.<BR><BR>This follows a global transaction between GlaxoSmithKline plc, UK(GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis.<BR><BR>The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity to build an even stronger, sustainable global vaccines business. The transaction will enhance GSKs vaccines portfolio and bring together its expertise in virology, bacterial infection and technological platforms to deliver a reliable supply of high quality vaccines.